In animal models, studies aimed at controlling rheumatoid arthritis and cell damage by ischemia/reperfusion through inhibition of PARP-1 activity began as early as in the 1990s, using first (such as nicotinamide) and second generation (PJ34, DPQ) pharmacological inhibitors [145,146]. This evidence concerns the gene PARP1 and rheumatoid arthritis.